Recro Pharma

REPH NASDAQ
9.65
-0.22
-2.23%
After Hours: 9.65 0 0.00% 16:39 06/26 EDT
Open
9.87
Prev Close
9.87
High
9.91
Low
9.61
Volume
106.02K
Avg Vol (3M)
395.55K
52 Week High
10.32
52 Week Low
4.780
% Turnover
0.48%
Market Cap
214.05M
1D
5D
1M
3M
1Y
5Y

Company Profile

Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.
MORE >

Recently

Name
Price
%Change